Adalimumab biosimilars differ from adalimumab in approved indications, concentration and dosage, and formulation.
This article was originally published on Pharmacy Times®. This version has been lightly edited.
Biosimilars play a crucial role in increasing access to lifesaving medications at potentially lower costs. According to the FDA, biosimilars are safe and effective, providing treatment for various illnesses, including chronic skin and bowel diseases, arthritis, kidney conditions, and cancer.1
Image credit: DachAI - stock.adobe.com
Adalimumab (Humira; AbbVie) is one of the leading products in the biologics market, often used to treat immune and inflammatory conditions. Unlike other biosimilars, adalimumab biosimilars have unique interchangeability and concentration considerations that impact pharmacy practices. Understanding the availability and considerations surrounding these products is essential—emphasizing the pharmacists’ role in educating patients on their use and workflow.2,3
As a biological medicine, adalimumab is made from proteins or other substances produced by the body. It is used to reduce inflammation by acting on the immune system, treating swelling caused by rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, and uveitis.3 The injectable treats these autoimmune conditions in adults and children by blocking the tumor necrosis factor (TNF) protein, which is a known cause of inflammation in the body.4
Adalimumab was first approved by the FDA in December 2002 and is available in several different doses, ranging from 10 mg to 80 mg.4,5 Since its initial approval, 10 adalimumab biosimilars have been approved in the US. However, adalimumab biosimilars differ from adalimumab in approved indications, concentration and dosage, and formulation.4
Pharmacists play a primary role in the landscape of adalimumab biosimilars, as many are indicated for similar treatment and are available in comparable doses, requiring a treatment expert to stay abreast of dosage and treatment requirements for each patient. Ensuring proper selection, dispensing, and monitoring of these biosimilars are crucial for patient outcomes. As the biosimilars landscape continues to evolve, pharmacists can educate health care providers and patients on the availability and benefits of adalimumab biosimilars while addressing concerns about their safety and efficacy.6
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilar Natalizumab-sztn Shows Comparable Efficacy and Safety to Tysabri in RRMS
March 25th 2025Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its potential as a cost-effective treatment option.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.